The addition of pembrolizumab (Keytruda) to docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC) did not improve overall or radiographic progression-free survival versus ...

PURPOSE: To evaluate the feasibility and efficacy of a sequential administration of four cycles of docetaxel (100 mg/m 2 every 3 weeks) followed by four cycles of doxorubicin and cyclophosphamide (AC; ...

No comparisons of different doses of docetaxel-capecitabine in patients with advanced gastric cancer have been performed. All approaches to optimise docetaxel–fluoropyrimidine-based regimens focus on ...

The small molecule from BeyondSpring is currently in late-stage clinical development in non–small cell lung cancer and for prevention of chemotherapy-induced neutropenia. CIN in patients undergoing ...

A total of 82 patients with HRPC were included. Of these, 71 patients were selected for second-line chemotherapy based on two or more consecutive increases in PSA not <14 days apart and/or objective ...

Of the 256 patients enrolled onto this trial, 222 completed the full treatment protocol. There were no unexpected toxicities, and induction chemotherapy did not increase perioperative morbidity. The ...

SAN DIEGO -- The use of sequential intravesical gemcitabine and docetaxel appeared effective and well tolerated in patients with high-risk non-muscle invasive bladder cancer (NMIBC) following the ...

UPPSALA, SWEDEN – LIDDS AB (publ) announced today that the next step in the development of NanoZolid®-formulated docetaxel (nanodotax) will be to conduct a short clinical study to understand the ...

Treatment with nedaplatin and docetaxel produced significantly longer OS compared with cisplatin and docetaxel in patients with advanced or relapsed squamous cell lung cancer, according to the results ...

CHICAGO — A study examining the combination of the antiangiogenic agent sunitinib and docetaxel failed to meet its primary endpoint in women with newly diagnosed advanced breast cancer, bringing into ...

Relmada Therapeutics is advancing NDV-01, a novel intravesical therapy for NMIBC, into phase 3 clinical trials, with Max ...

LUGANO-MADRID, 10 September, 2017 - Ramucirumab plus docetaxel improves progression-free survival in patients with advanced or metastatic urothelial cancer who have progressed on platinum-based ...